AI Article Synopsis

  • This study investigates the effectiveness of using the MIB-1 labeling index from immunostained bladder cancer specimens to predict patient outcomes, such as recurrence, progression, and survival.
  • Analysis of a group of 301 patients showed strong links between tumor characteristics (like stage and age) and overall survival rates, with MIB-1 proving valuable for recurrence-free survival for specific tumor stages (Ta and T1).
  • The findings suggest that while traditional staging and grading are important, MIB-1 immunostaining can enhance predictions for patient prognosis and should be considered in treatment decisions.

Article Abstract

Background: Staging and grading of transitional cell carcinoma of the bladder are generally viewed as indicators of prognosis and form the basis of therapy, but they do not predict outcome accurately. This study was designed to evaluate the value for predicting recurrence, progression, and survival of proliferation fraction in transitional cell carcinoma of the bladder determined by immunostaining of histopathologic specimens with the monoclonal antigen MIB-1.

Methods: In a prospectively followed group of 301 patients with transitional cell carcinoma of the bladder, formalin fixed tumor specimens were immunostained and the MIB-1 labeling index was determined. Crude survival, progression free survival, and recurrence free survival (for patients with Ta and T1 tumors) were assessed in univariate and multivariate analysis according to stage, grade, mitotic index of the tumor, and patient age. The median value of continuous variables was used as a cutoff point in statistical analysis.

Results: In univariate analysis there was a strong association between all included factors and crude survival, progression free survival, and recurrence free survival with a median follow-up period of 60 months. In multivariate analysis, crude survival and progression free survival were determined by stage (P = 0.0001) and age (P = 0.0001). Recurrence free survival for patients with Ta and T1 tumors was determined by MIB-1 labeling index (P = 0.0317), mitotic index (P = 0.0229), and age (P = 0.0001).

Conclusions: MIB-1 immunostaining in transitional cell carcinoma of the bladder correlated well with grade, stage, and clinical outcome. In multivariate analysis, proliferation fraction had prognostic value in predicting recurrence free survival for patients with Ta and T1 tumors, whereas stage and age appeared to be predictors of progression free survival.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(20000601)88:11<2598::aid-cncr24>3.0.co;2-nDOI Listing

Publication Analysis

Top Keywords

free survival
32
transitional cell
20
cell carcinoma
20
carcinoma bladder
20
progression free
16
recurrence free
16
survival
12
crude survival
12
survival progression
12
survival patients
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!